1. Home
  2. WST vs ILMN Comparison

WST vs ILMN Comparison

Compare WST & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • ILMN
  • Stock Information
  • Founded
  • WST 1923
  • ILMN 1998
  • Country
  • WST United States
  • ILMN United States
  • Employees
  • WST N/A
  • ILMN N/A
  • Industry
  • WST Medical/Dental Instruments
  • ILMN Medical Specialities
  • Sector
  • WST Health Care
  • ILMN Health Care
  • Exchange
  • WST Nasdaq
  • ILMN Nasdaq
  • Market Cap
  • WST 23.2B
  • ILMN 23.6B
  • IPO Year
  • WST N/A
  • ILMN 2000
  • Fundamental
  • Price
  • WST $318.22
  • ILMN $147.64
  • Analyst Decision
  • WST Buy
  • ILMN Buy
  • Analyst Count
  • WST 3
  • ILMN 19
  • Target Price
  • WST $460.33
  • ILMN $162.67
  • AVG Volume (30 Days)
  • WST 475.9K
  • ILMN 2.1M
  • Earning Date
  • WST 10-24-2024
  • ILMN 02-06-2025
  • Dividend Yield
  • WST 0.26%
  • ILMN N/A
  • EPS Growth
  • WST N/A
  • ILMN N/A
  • EPS
  • WST 6.74
  • ILMN N/A
  • Revenue
  • WST $2,876,400,000.00
  • ILMN $4,390,000,000.00
  • Revenue This Year
  • WST N/A
  • ILMN N/A
  • Revenue Next Year
  • WST $6.22
  • ILMN $4.28
  • P/E Ratio
  • WST $47.21
  • ILMN N/A
  • Revenue Growth
  • WST N/A
  • ILMN N/A
  • 52 Week Low
  • WST $265.00
  • ILMN $97.36
  • 52 Week High
  • WST $413.70
  • ILMN $156.66
  • Technical
  • Relative Strength Index (RSI)
  • WST 49.85
  • ILMN 56.37
  • Support Level
  • WST $313.92
  • ILMN $138.88
  • Resistance Level
  • WST $327.47
  • ILMN $151.75
  • Average True Range (ATR)
  • WST 6.84
  • ILMN 4.96
  • MACD
  • WST -0.82
  • ILMN 0.76
  • Stochastic Oscillator
  • WST 51.33
  • ILMN 81.01

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: